Neuroinflammation has been involved in neurodegenerative diseases and acute brain injury such as stroke. monocytes chemotactic protein -1-induced protein -1 (Mcpip1) is a multifunctional protein action is known to have pro-apoptotic or anti-apoptotic depending on the nature of the experimental arrangement. However, its role in brain damage after asphyxia in the developing brain has not been studied. Therefore, we explored the role Mcpip1 on brain injury after hypoxia-ischemia in neonatal rats.

At postnatal day 7, Mcpip1-deficient and wild-type mice carotid artery ligation and exposure to hypoxia (8% oxygen). After a hypoxic-ischemic insult, we determine the time-course of cell death of apoptosis and expression levels of genes that encode proinflammatory factors. Mcpip1 impact on long-term brain damage rated one week after hypoxia-ischemia by cresyl violet staining.

We found caspase- 3 significantly increased activity in the ipsilateral brain tissue within 12-24 hours after hypoxia-ischemia. There is a marked increase in levels of mRNA transcripts that encode Mcpip1, TNF, and CCL2 in the ipsilateral brain tissue 6-48 hours after hypoxia-ischemia. We found caspase- hypoxia-ischemia-induced 3 and the activity levels of proinflammatory genes are inactivated in Mcpip1-KO mice compared to wild-type mice.

Histological assessment revealed that hypoxia-ischemia-induced brain tissue loss was significantly attenuated in the hippocampus of Mcpip1-KO mice compared to wild-type mice (9.0 ± 5.6% vs 3 3 0.9 ± 11.0%, P <0.05). Our data show that Mcpip1 contributes to acute and delayed brain damage, in part, through the regulation of neuroinflammation after hypoxic-ischemic insult in the developing rat brain.

Monocyte chemotactic protein-1-induced protein 1 contributes to neuronal injury following hypoxic-ischemia in the neonatal mouse brain
Monocyte chemotactic protein-1-induced protein 1 contributes to neuronal injury following hypoxic-ischemia in the neonatal mouse brain

MCP-1 priming Enhanced Mesenchymal stromal cells Therapeutic Effect on Contact Hypersensitivity by Enabling COX2-PGE2 / STAT3 Pathway mesenchymal stromal

cells (MSC) has become a promising treatment for inflammation-related diseases, and the efficacy of their therapy mainly depends on the crosstalk between the MSC and inflammation. However, methods to improve the efficiency of immunosuppressive of MSC in different diseases still need to be developed. In this study, we investigated whether preconditioning MSC inflammatory cytokines associated with the disease can improve their immunosuppressive properties and increasing the success of therapy.

In a mouse model of contact hypersensitivity (CHS), an inflammatory profile screening revealed that among all the cytokines tested, monocytes chemotactic protein -1 (MCP- 1) exhibited the lowest level increased significantly in the local microenvironment. As expected, MSC asphalt with MCP-1 (P-MSCs) exhibited an enhanced ability to downregulate the secretion of proinflammatory cytokines, induce regulatory T cells, inhibiting T cell proliferation, and the polarization of M2-type macrophages.

In vivo experiments showed that P-MSCs alleviated ear swelling and local production of proinflammatory cytokines is more effective than MSC controls. Mechanically, MCP-1 can significantly activate signal transducer and activator of transcription 3 (STAT 3 ) signaling pathway and induces the expression of cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2) in the MSC. STAT 3 inhibitor reversed MCP-1-mediated increase their immunosuppressive capabilities.

ATP disodium salt
B3304-5.1 10 mM (in 1mL H2O)
EUR 129.6
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt
B3304-50 50 mg
EUR 153.6
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt
B3304-S Evaluation Sample
EUR 97.2
Description: ATP Disodium salt is a P2 purinoceptor agonist.

BCA disodium salt
2810-100G each
EUR 1038

BCA disodium salt
2810-1G each
EUR 144

BCA disodium salt
2810-500G each
EUR 3126

BCA disodium salt
2810-5G each
EUR 261.6

UDP disodium salt
B7278-5.1 10 mM (in 1mL DMSO)
EUR 129.6

UDP disodium salt
B7278-50 50 mg
EUR 150

ADA disodium salt
GB0256-100G 100 g
EUR 132

ADA disodium salt
GB0256-500G 500 g
EUR 409.2

ATP (disodium salt)
HY-B0345A 10mM/1mL
EUR 135.6

DNQX disodium salt
B5288-100 100 mg
EUR 334.8

DNQX disodium salt
B5288-25 25 mg
EUR 153.6

DNQX disodium salt
B5288-50 50 mg
EUR 223.2

NADH, disodium salt
2735-1000 each
EUR 202.8

NADH, disodium salt
2735-500 each
EUR 170.4

NADH, disodium salt
2735-5000 each
EUR 652.8

NADP, disodium salt
2736-100 each
EUR 183.6

NADP, disodium salt
2736-1000 each
EUR 940.8

NADP, disodium salt
2736-500 each
EUR 548.4

NBQX disodium salt
2759-25 each
EUR 770.4

NBQX disodium salt
2759-5 each
EUR 248.4

BCIP disodium salt
BB1171 500mg
EUR 279.24

NBQX disodium salt
B6566-10 10 mg
EUR 266.4

NBQX disodium salt
B6566-25 25 mg
EUR 466.8

NBQX disodium salt
B6566-5 5 mg
EUR 166.8

NBQX disodium salt
B6566-50 50 mg
EUR 819.6

CNQX disodium salt
B6567-1 1 mg
EUR 160.8

CNQX disodium salt
B6567-10 10 mg
EUR 258

CNQX disodium salt
B6567-50 50 mg
EUR 895.2

NADH (disodium salt)
HY-F0001 10mM/1mL
EUR 135.6

NADP (disodium salt)
HY-F0002A 500mg
EUR 325.2

cGAMP disodium salt
2435-100 each
EUR 235.2

POPSO, disodium salt
PB4959 25g
EUR 92.36

cGAMP disodium salt
GL2101-100UG 100 ug
EUR 192

cGAMP disodium salt
GL2101-500UG 500 ug
EUR 398.4

PIPES disodium salt
GB1799-100G 100 g
EUR 132

PIPES disodium salt
GB1799-250G 250 g
EUR 217.2

PIPES disodium salt
GB1799-25G 25 g
EUR 84

PIPES disodium salt
GB1799-500G 500 g
EUR 370.8

POPSO disodium salt
GB6170-100G 100 g
EUR 322.8

POPSO disodium salt
GB6170-25G 25 g
EUR 151.2

CL 316243 disodium salt
B6766-1 1 mg
EUR 130.8
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt
B6766-10 10 mg
EUR 351.6
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt
B6766-5 5 mg
EUR 247.2
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

Cefotetan disodium salt
GA5476-100MG 100 mg
EUR 103.2

Cefotetan disodium salt
GA5476-1G 1 g
EUR 217.2

Etidronate disodium salt
GP3560-1G 1 g
EUR 208.8

Lobenzarit disodium salt
GP3753-100MG 100 mg
EUR 274.8

Methoxatin (disodium salt)
HY-100196A 10mM/1mL
EUR 223.2

Fluorescein, disodium salt
FB0203 100g
EUR 76.7

Ticarcillin disodium salt
GA1874-100MG 100 mg
EUR 60

Ticarcillin disodium salt
GA1874-1G 1 g
EUR 132

Ticarcillin disodium salt
GA1874-500MG 500 mg
EUR 93.6

Balsalazide disodium salt
GP7647-1G 1 g
EUR 132

Hypoxanthine Disodium Salt
B1185-1G each
EUR 130.8

Hypoxanthine Disodium Salt
B1185-5G each
EUR 288

Phosphomycin disodium salt
GA7173-1G 1 g
EUR 84

Phosphomycin disodium salt
GA7173-25G 25 g
EUR 346.8

Phosphomycin disodium salt
GA7173-5G 5 g
EUR 160.8

ADA buffer, disodium salt
AB0005 25g
EUR 79.84

Carbenicillin, Disodium Salt
A2511-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

Carbenicillin, Disodium Salt
A2511-50 50 mg
EUR 157.2
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

Carbenicillin disodium salt
GA1299-10G 10 g
EUR 274.8

Carbenicillin disodium salt
GA1299-1G 1 g
EUR 103.2

Carbenicillin disodium salt
GA1299-250MG 250 mg
EUR 70.8

Carbenicillin disodium salt
GA1299-25G 25 g
EUR 409.2

Carbenicillin disodium salt
GA1299-5G 5 g
EUR 189.6

Eosin Y disodium salt (C.I. 45380)
GT2884-100G 100 g
EUR 93.6

Eosin Y disodium salt (C.I. 45380)
GT2884-250G 250 g
EUR 151.2

Eosin Y disodium salt (C.I. 45380)
GT2884-25G 25 g
EUR 55.2

Phosphoramidon Disodium Salt
B4790-25 25 mg
EUR 588
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

Phosphoramidon Disodium Salt
B4790-5 5 mg
EUR 226.8
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

Pamoic acid disodium salt
B7638-10 10 mg
EUR 576

Pamoic acid disodium salt
B7638-50 50 mg
EUR 2233.2

Pamoic acid disodium salt
GK6564-100G 100 g
EUR 103.2

Pamoic acid disodium salt
GK6564-250G 250 g
EUR 170.4

Pamoic acid disodium salt
GK6564-25G 25 g
EUR 64.8

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*
11610 25 mg
EUR 86

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*
11612 10 g
EUR 1099

Phosphocreatine disodium salt
B7648-25 25 mg
EUR 235.2

UDP-GlcNAc Disodium Salt
HY-112174 5mg
EUR 198

Dimethylglyoxime disodium salt
DD1221 100g
EUR 76.7

EDTA, Disodium Salt, Dihydrate
CH032 500 g
EUR 195.6

EDTA, Disodium Salt, Dihydrate
CH033 1.0 kg
EUR 234

EDTA, Disodium Salt, Dihydrate
CH034 2.5 kg
EUR 400.8

MUP, disodium salt, trihydrate
M0740 1g
EUR 112.2

EDTA disodium salt dihydrate
GE3023-100G 100 g
EUR 48

EDTA disodium salt dihydrate
GE3023-1KG 1 kg
EUR 84

EDTA disodium salt dihydrate
GE3023-250G 250 g
EUR 55.2

EDTA disodium salt dihydrate
GE3023-500G 500 g
EUR 64.8

EDTA disodium salt dihydrate
GE3023-5KG 5 kg
EUR 180

EDTA, disodium salt, dihydrate
EB0185 500g
EUR 84.01

EDTA zinc (II), disodium salt
EB6666 100g
EUR 77.75

EDTA Disodium Salt 0.02m (0.04n)
ED20021 1L
EUR 157.2

EDTA copper(II) disodium salt
EB0434 250g
EUR 100.72

DL-Malic acid disodium salt
GX1468-100G 100 g
EUR 55.2

DL-Malic acid disodium salt
GX1468-500G 500 g
EUR 90

Clodronate disodium salt hydrate
GP6103-1G 1 g
EUR 103.2

5'-Guanylic acid (disodium salt)
HY-W010970 10mM/1mL
EUR 135.6

Boc-Cys(SO3H)-OH · disodium salt
A-3625.0001 1.0g
EUR 138
Description: Sum Formula: C8H13NNa2O7S2; CAS# [163558-29-0]

Boc-Cys(SO3H)-OH · disodium salt
A-3625.0005 5.0g
EUR 370.8
Description: Sum Formula: C8H13NNa2O7S2; CAS# [163558-29-0]

Boc-Cys(SO3H)-OH · disodium salt
A-3625.0025 25.0g
EUR 1371.6
Description: Sum Formula: C8H13NNa2O7S2; CAS# [163558-29-0]

5g Carbenicillin Disodium Salt P
46-100-RG EACH
EUR 327.6

Fmoc-Cys(SO3H)-OH · disodium salt
B-2415.0001 1.0g
EUR 138
Description: Sum Formula: C18H15NNa2O7S2; CAS# [163558-30-3]

Fmoc-Cys(SO3H)-OH · disodium salt
B-2415.0005 5.0g
EUR 370.8
Description: Sum Formula: C18H15NNa2O7S2; CAS# [163558-30-3]

Fmoc-Cys(SO3H)-OH · disodium salt
B-2415.0025 25.0g
EUR 1371.6
Description: Sum Formula: C18H15NNa2O7S2; CAS# [163558-30-3]

L-Tyrosine disodium salt hydrate
GE4061-100G 100 g
EUR 100.8

L-Tyrosine disodium salt hydrate
GE4061-25G 25 g
EUR 57.6

L-Tyrosine disodium salt hydrate
GE4061-50G 50 g
EUR 73.2

Hydroxy naphthol blue disodium salt
GT4927-100G 100 g
EUR 122.4

Hydroxy naphthol blue disodium salt
GT4927-25G 25 g
EUR 74.4

Volumetric Sol EDTA (DiSodium Salt) 0.01785M (0.0357N)
ED2003571 1L
EUR 112.28

BCA (Bicinchoninic acid), disodium salt
BB0260 5g
EUR 185.28

Uridine 5'-diphosphate disodium salt
GC9934-100MG 100 mg
EUR 88.8

Uridine 5'-diphosphate disodium salt
GC9934-1G 1 g
EUR 313.2

Uridine 5'-diphosphate disodium salt
GC9934-250MG 250 mg
EUR 132

Uridine 5'-diphosphate disodium salt
GC9934-25MG 25 mg
EUR 62.4

Uridine 5'-diphosphate disodium salt
GC9934-500MG 500 mg
EUR 194.4

EDTA magnesium disodium salt hydrate
GE3956-100G 100 g
EUR 79.2

EDTA magnesium disodium salt hydrate
GE3956-1KG 1 kg
EUR 294

EDTA magnesium disodium salt hydrate
GE3956-250G 250 g
EUR 122.4

EDTA magnesium disodium salt hydrate
GE3956-25G 25 g
EUR 54

EDTA magnesium disodium salt hydrate
GE3956-500G 500 g
EUR 184.8

EDTA manganese disodium salt hydrate
GX6009-100G 100 g
EUR 122.4

EDTA manganese disodium salt hydrate
GX6009-250G 250 g
EUR 208.8

EDTA manganese disodium salt hydrate
GX6009-25G 25 g
EUR 69.6

EDTA manganese disodium salt hydrate
GX6009-500G 500 g
EUR 322.8

L-?-Hydroxyglutaric Acid Disodium Salt
B2812-25 each
EUR 418.8

L-?-Hydroxyglutaric Acid Disodium Salt
B2812-5 each
EUR 157.2

DL-?-Hydroxyglutaric acid disodium salt
A3837-100 100 mg
EUR 223.2
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

DL-?-Hydroxyglutaric acid disodium salt
A3837-25 25 mg
EUR 141.6
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

DL-?-Hydroxyglutaric acid disodium salt
A3837-50 50 mg
EUR 184.8
Description: IC50: N/AD-?-Hydroxyglutaric acid, an ?-hydroxy acid formed from the hydrolysis of (R)-5-oxo-2-tetrahydrofurancarboxylic acid, is over-produced in the human neurometabolic disease D-?-hydroxyglutaric aciduria.

NADH disodium salt, trihydrate, reduced
NB0642 1g
EUR 98.63

Succinic acid disodium salt, anhydrous
GK7702-100G 100 g
EUR 51.6

Succinic acid disodium salt, anhydrous
GK7702-1KG 1 kg
EUR 112.8

Succinic acid disodium salt, anhydrous
GK7702-250G 250 g
EUR 62.4

Succinic acid disodium salt, anhydrous
GK7702-500G 500 g
EUR 79.2

Succinic acid disodium salt, anhydrous
GK7702-5KG 5 kg
EUR 294

Collectively, our findings indicate that MCP-1 related CHS conditioning increases immunomodulatory effects of MSC and enhanced their therapeutic efficacy in CHS. Improving the effectiveness of immunosuppressive MSC by preconditioning inflammatory cytokines associated with a particular disease may provide new strategies for MSC-based therapy for inflammatory disease.